ArticleEndocrine2025
Indications for primary aldosteronism screening in people with hypertension and hyperparathyroidism: a multi-centre cohort study.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeParathyroid hormone (PTH) excess is associated with hypertension while elevated PTH has been observed in primary aldosteronism (PA). This study aimed to determine the proportion of patients with hyperparathyroidism who met Endocrine Society criteria for PA screening, and to assess current screening practices.
methodsMulti-centre retrospective cohort study including patients attending outpatient endocrine clinics at three tertiary health services in Victoria, Australia between 2015-2019. Patients were included if they had an elevated PTH level and excluded if they had a secondary cause of hyperparathyroidism or a prior diagnosis of PA. Demographic, clinical and biochemical data were extracted from electronic medical records.
resultsOf 275 patients with hyperparathyroidism, hypertension was present in 51.6%; including 62.4% of patients with hypercalcaemia and 35.5% of those with normocalcaemia. Overall,15.6% (43/275) had a guideline indication for PA screening, including 21.8% (36/165) of those with hypercalcaemia and 6.4% (7/110) of those with normocalcaemia. Of those with hypertension, 30% (43/142) had a guideline indication for PA screening. The most common indication for screening was hypertension and hypokalaemia (16/43). Despite this, only 9.3% (4/43) were screened, with one confirmed PA diagnosis.
conclusionHypertension is common in patients with hyperparathyroidism. A third of patients with hyperparathyroidism and hypertension had a guideline indication for PA screening, however screening remains substantially under-utilised. A prospective study is needed to evaluate the prevalence and impact of PA in patients with hyperparathyroidism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.